SuperworthHeartflow HTFL
- Market cap
- $4.9B
- PE
- n/m
- a loss over the last year
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- 23.3×
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- $212.1M
- +43% on a year ago
- Net margin
- −55.8%
- Free cash flow yield
- −1.2%
Heartflow trades at 23.3× sales. Its trailing earnings are negative, so it has no PE. Revenue was $212.1M over the last twelve months, up 43% on a year earlier with a −56% net margin.
Charts
Financials
| Income statement | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|
| $26.8M | $31.1M | $32.9M | $35M | $37.2M+39% | $43.4M+40% | $46.3M+41% | $49.1M+41% | $52.6M+41% | $64.1M+48% | |
| Cost of revenue | $7.4M | $7.2M | $8M | $8.7M | $9.3M+25% | $10.6M+48% | $10.9M+36% | $10.1M+15% | $10.4M+13% | $10.9M+2% |
| Gross profit | $19.4M | $23.8M | $24.9M | $26.3M | $27.9M+44% | $32.8M+38% | $35.4M+42% | $39.1M+49% | $42.2M+51% | $53.2M+62% |
| R&D | $9.4M | $9.9M | $11.9M | $12.3M | $13.9M+48% | $15M+51% | $17.3M+46% | $18.7M+52% | $21.6M+55% | $26.3M+75% |
| SG&A | $26M | $28.1M | $28M | $30M | $31.5M+21% | $31.5M+12% | $33.2M+19% | $38.1M+27% | $42.6M+35% | $44.8M+43% |
| −$16.1M | −$14.2M | −$14.9M | −$16.1M | −$17.5M+9% | −$13.7M−3% | −$15.1M+1% | −$17.8M+11% | −$29.5M+69% | −$17.9M+31% | |
| Interest expense | $6.2M | $6.1M | $5.3M | $5.2M | $5.1M−18% | $6.6M+9% | $3.5M−35% | $8K−100% | $3K−100% | $0 |
| Pre-tax income | −$21M | −$23.3M | −$19.1M | −$33M | −$32.3M+54% | −$9.1M−61% | −$50.8M+166% | −$24.6M−26% | −$27.4M−15% | −$15.7M+72% |
| −$72K | $120K | $0 | $5K | $0 | $59K−51% | $30K | −$165K | $23K | $22K−63% | |
| Net income | −$20.9M | −$23.4M | −$19.1M | −$33M | −$32.3M+55% | −$9.2M−61% | −$50.9M+166% | −$24.4M−26% | −$27.4M−15% | −$15.7M+71% |
| −$4.23 | −$4.66 | −$3.43 | −$5.59 | −$5.25+24% | −$1.46−69% | −$1.04−70% | −$0.29−95% | −$0.32−94% | −$0.18−88% | |
| 4.9M | 5M | 5.6M | 5.9M | 6.2M+25% | 6.3M+26% | 49.1M+779% | 84.8M+1339% | 85.6M+1289% | 86.4M+1268% |
Revenue: Q1 FY24 and Q1 FY25: 6 months less the 3 months printed beside them.
Cost of revenue: Q1 FY24 and Q1 FY25: 6 months less the 3 months printed beside them.
Gross profit: Q1 FY24 and Q1 FY25: 6 months less the 3 months printed beside them.
R&D: Q1 FY24 and Q1 FY25: 6 months less the 3 months printed beside them.
SG&A: Q1 FY24 and Q1 FY25: 6 months less the 3 months printed beside them.
Operating income: Q1 FY24 and Q1 FY25: 6 months less the 3 months printed beside them.
Interest expense: Q1 FY24 and Q1 FY25: 6 months less the 3 months printed beside them.
Pre-tax income: Q1 FY24 and Q1 FY25: 6 months less the 3 months printed beside them.
Income tax: Q1 FY24 and Q1 FY25: 6 months less the 3 months printed beside them.
Net income: Q1 FY24 and Q1 FY25: 6 months less the 3 months printed beside them.
EPS, diluted: 4 periods, Q1 FY24 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: Q1 FY24: share-days: the 6-month average less the second quarter's. Q4 FY24 and Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Medical - Instruments & Supplies nearest Heartflow's size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| HTFLHeartflow | $4.9B | n/m | n/a | 23.3× | +43% | −55.8% | |
| VNTVontier | $4.6B | 14.3× | 13.5× | 1.5× | +1% | 11.3% | |
| HAEHaemonetics | $5.4B | 58.1× | 51.6× | 4.0× | +0% | 7.1% | |
| BMIBadger Meter | $4.4B | 35.3× | 47.6× | 5.0× | −2% | 14.3% | |
| MMSIMerit Medical Systems | $5.6B | 38.6× | 57.5× | 3.5× | +10% | 9.2% | |
| ICUIICU Medical | $4.2B | 141× | 57.8× | 1.9× | −9% | 1.4% | |
| NVSTEnvista | $3.8B | 40.7× | 27.9× | 1.3× | +12% | 3.3% | |
| MSAMSA Safety | $7B | 22.7× | 36.3× | 3.6× | +6% | 16.1% | |
| WRBYWarby Parker | $3.2B | 370× | 366× | 3.5× | +11% | 0.8% | |
| ATRCAtriCure | $3B | 281× | 58.4× | 5.3× | +14% | 1.9% | |
| PODDInsulet | $10.3B | 27.9× | 63.0× | 3.4× | +29% | 12.3% | |
| Peer median | $4.5B | 39.6× | 54.5× | 3.5× | +8% | 8.2% |
Investors who own it
Investors we follow who held Heartflow at the end of Jun 30, 2026, from their 13F filings.
- Ron BaronBaron Capital0.1% of portfoliotrimmed
More on Heartflow
Each number over time
Where it ranks
Its groups
About
- Industry
- Medical - Instruments & Supplies
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .